Persistence of BCR/ABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse.
Hughes
T P
TP
Royal Postgraduate Medical School, London, UK.
O'Shea
P
P
Morgan
G
G
Martiat
P
P
Goldman
J M
JM
D014408:Biomarkers, Tumor / Q000032:analysis*; D016026:Bone Marrow Transplantation; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis*; D012334:RNA, Neoplasm / Q000032:analysis*; D012307:Risk Factors
D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D016044:Fusion Proteins, bcr-abl